Major Program
Supportive Care and Symptom Management
Research Group
Community Oncology and Prevention Trials
Sponsor
Donna Hammond, PhD
Status
Terminated
NCT ID
NCT03642990
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.
Intervention
Nicotinamide Riboside
Condition
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV, Endometrial Cancer Stage IV
Investigators
Donna L Hammond, PhD, Alexandra Thomas, MD